Medications

Trial results of new drug for generalized myasthenia gravis

Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...

Diseases, Conditions, Syndromes

Team uncovers largest US outbreak of neurologic disease to date

The Lancet Infectious Diseases recently published the results of an observational study led by researchers on Children's Hospital Colorado Infectious Disease and Neurology teams, along with counterparts at the Centers for ...

Parkinson's & Movement disorders

Restless sleep may be an early sign of Parkinson's disease

Restless sleep could be a sign of a disorder associated with diseases of the brain. Researchers from Aarhus University conducted a case-control study on the condition of the dopamine-producing nerve cells in the brain and ...

Alzheimer's disease & dementia

Medical nutrition-drink may affect development of early Alzheimer's

In a new study, an international research team shows that a medical nutrition-drink, consisting of, among other things, essential fatty acids and vitamins, may have an impact on disease development in patients with so-called ...

page 1 from 8